CRISIL Predicts Indian Pharma Sales To Rise 7%-9% In FY23

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Due to challenges in export sales in the regulated markets and a large base effect in the home formulations sector, the Indian pharmaceutical industry is anticipated to achieve moderate revenue growth of 7-9% in the current fiscal.

Because of ongoing pricing pressure in the US generics market, high input and freight costs, which offset moderate revenue growth, and operating profitability declining by another 200–250 basis points (bps) after a 130 bps decline in the previous fiscal, it was predicted.

The rating agency’s projections are based on data from 184 drug manufacturers, who together generate 55% of the industry’s annual revenue of Rs. 3.4 lakh crore.

According to CRISIL, the Indian formulations market is anticipated to expand by 7-9% this fiscal year, up from 15% growth last year. This growth will be driven by new product releases and a 6-8% average price rise approved by the National Pharmaceutical Pricing Authority in March 2022.

While demand for COVID-19-induced medications and vitamins is waning, it was also noted that this fiscal year’s demand is likely to be driven by a rise in the use of some chronic medications related to lifestyle, as well as a few acute medications, particularly in the dermatology and ophthalmology segments.

Given ongoing price pressure, according to CRISIL Research Director Aniket Dani, the expansion of the US generics market will slow.

However, some blushes are spared by the decline of the rupee. Exports to other controlled markets could expand more quickly as multinational corporations geographically broaden, he added. 

Latest stories

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back